Correct Answer: A. Neutral endopeptidase inhibitor
Sacubitril is a neutral endopeptidase (NEP) inhibitor that forms the cornerstone of the ARNI (Angiotensin Receptor-Neprilysin Inhibitor) class, marketed as sacubitril/valsartan (Entresto®) in India. NEP is an enzyme that degrades natriuretic peptides (ANP and BNP), which are cardioprotective hormones that promote vasodilation, sodium excretion, and reduced cardiac remodeling. By inhibiting NEP, sacubitril increases circulating levels of these natriuretic peptides, enhancing their beneficial effects on the failing heart. The drug is approved for chronic heart failure with reduced ejection fraction (HFrEF) and has demonstrated superior outcomes compared to ACE inhibitors alone in landmark trials like PARADIGM-HF. In the Indian context, sacubitril/valsartan is increasingly used as a first-line agent for HFrEF, particularly in urban centers, replacing traditional ACE inhibitor monotherapy. The combination with valsartan (an ARB) provides dual benefit: NEP inhibition plus angiotensin II receptor blockade, synergistically reducing cardiac afterload and preventing maladaptive remodeling. This represents a paradigm shift in heart failure management per current Indian guidelines.
Why the other options are wrong
B. Renin inhibitor — Renin inhibitors (e.g., aliskiren) directly block the first step of the RAAS cascade. Sacubitril does not inhibit renin; it works downstream by enhancing natriuretic peptides. This is a trap for students who confuse RAAS blockade mechanisms—sacubitril's benefit is independent of renin inhibition and works through a completely different pathway (NEP inhibition). C. Angiotensin II inhibitor — While sacubitril/valsartan combination includes valsartan (an ARB that blocks angiotensin II receptors), sacubitril itself is NOT an angiotensin II inhibitor. Sacubitril's primary mechanism is NEP inhibition. This option conflates the drug with its partner agent—a common NBE trap for students who remember only that sacubitril is used with an ARB. D. ACE inhibitor — ACE inhibitors (e.g., lisinopril, ramipril) block conversion of angiotensin I to angiotensin II. Sacubitril is structurally and mechanistically distinct—it is a NEP inhibitor, not an ACE inhibitor. This trap exploits confusion between different RAAS-modulating drug classes; sacubitril represents a novel mechanism beyond traditional RAAS blockade.
High-Yield Facts
- Sacubitril is a neutral endopeptidase (NEP) inhibitor that increases natriuretic peptide (ANP/BNP) levels by preventing their enzymatic degradation.
- ARNI (sacubitril/valsartan) is superior to ACE inhibitors alone in HFrEF and is now a cornerstone therapy in Indian heart failure guidelines.
- Natriuretic peptides promote vasodilation, sodium excretion, and anti-fibrotic remodeling—effects amplified when NEP is inhibited.
- Sacubitril monotherapy is not used clinically; it is always combined with an ARB (valsartan) to provide dual RAAS and NEP blockade.
- PARADIGM-HF trial demonstrated 27% reduction in mortality/HF hospitalization with sacubitril/valsartan vs. enalapril in HFrEF patients.
Mnemonics
NEP = Natriuretic Endopeptidase Protease Sacubitril blocks the enzyme that destroys natriuretic peptides → peptides accumulate → heart benefits. When you see 'sacubitril,' think 'NEP inhibitor' and 'natriuretic peptide preservation.' ARNI = ARB + NEP Inhibitor Sacubitril/valsartan = ARB (valsartan) + NEP inhibitor (sacubitril). Dual mechanism: block angiotensin II and preserve natriuretic peptides. Use this to remember sacubitril is always paired with an ARB.
NBE Trap
NBE pairs sacubitril with RAAS-blocking options (renin inhibitor, ACE inhibitor, ARB) to exploit students' assumption that all modern heart failure drugs target the RAAS. Sacubitril's novelty lies in its orthogonal mechanism—NEP inhibition—which is why it is combined with (not replaced by) ARBs.
Clinical Pearl
In Indian urban practice, sacubitril/valsartan is increasingly preferred over ACE inhibitors for newly diagnosed HFrEF because it addresses both RAAS excess and natriuretic peptide deficiency—a dual pathophysiologic hit that translates to better symptom relief and mortality reduction in real-world Indian cohorts.
_Reference: KD Tripathi Pharmacology Ch. 31 (CVS Drugs); Harrison Principles of Internal Medicine Ch. 235 (Heart Failure)_